Expert connection丨Prof. Yu and Prof. Powles: the phase 3 trial of First Line Maintenance Immunotherapy for Advanced Urothelial Carcinoma (JAVELIN Bladder 100)
At the 2020 ASCO conference, Professor Thomas Powles from Barts Cancer Institute and the London School of Medicine and Dentistry, UK, has reported the JAVELIN Bladder 100 study, which showed that patients with advanced urothelial cancer treated with avilumab as the first-line maintenance therapy followed with chemotherapy could significantly improve OS compared with the control group. In this interview, Professor Yu Wei from the first hospital of Peking University will talk to Professor Powles to share the main results of this study and the immunotherapy strategy for advanced urothelial cancer.
2020-06-23
尿路上皮癌